Product: Nodify XL2
-
Use Of A Blood-Based Biomarker May Expedite Diagnosis Of Malignant Nodules By Supporting Biopsy
-
Using a Blood Biomarker to Distinguish Benign From Malignant Pulmonary Nodules
-
Impact of an integrated classifier using biomarkers, clinical and imaging factors on clinical decisions making for lung nodules
-
Assessing a biomarker’s ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study
-
Budget Impact of a Blood-Based Integrated Classifier Test to Reclassify Risk of Pulmonary Nodules in a US Commercial Payer Setting
-
Budget Impact of a Blood-Based Integrated Classifier Test to Down Classify Riskof Pulmonary Nodules in a US Medicare Payer Setting
-
Shifting the Intervention Probability Curve for Lung Cancer Diagnosis Following Biomarker Implementation: A Novel Clinical Endpoint for Biomarker Clinical Trials
-
Comparison Of The Performance Of A Blood-Based Integrated Classifier In Risk Stratifying Incidental And Screening-Detected Pulmonary Nodules
-
Impact Of A Blood-Based Integrated Classifier To reclassify Lung Nodule Risk Across Nodule Size spectrum
-
Clinical Utility of the Nodify XL2® Blood-Based Risk Classifier for Management of Benign Pulmonary Nodules in a Real-World Observational Study